TCT-415 Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?

Dean J. Kereiakes; Stephen G. Ellis; Runlin Gao; Takeshi Kimura; Yoshinobu Onuma; Karine Piard‐Ruster; Yunlong Zhang; Kai Koo; Patrick W. Serruys; Gregg W. Stone

doi:10.1016/j.jacc.2016.09.550

Related publications

Article2020

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

Yoshinobu Onuma, Bernard Chevalier, Masafumi Ono, Ángel Cequier, Dariusz Dudek, Michael Haude, Didier Carrié, Manel Sabaté, Stephan Windecker, Richard Rapoza, Nick E.J. West, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Íñiguez, Patrick W. Serruys

EuroIntervention

Article2015

ACUTE RECOIL FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: THE ABSORB II TRIAL

Bernard Chevalier, Yuki Ishibashi, Yoshinobu Onuma, Patrick W. Serruys

Journal of the American College of Cardiology

Article2018

TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Patrick W. Serruys, Bernard Chevalier

Journal of the American College of Cardiology

Article2013

TCT-36 One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSORB EXTEND Trials.

Takashi Muramatsu, Yoshinobu Onuma, Robert J. Van Geuns, Bernard Chevalier, Tejas Patel, Ashok Seth, Roberto Diletti, Héctor M. García‐García, Cécile Dorange, Susan Veldhof, Wai‐Fung Cheong, Robert Whitbourn, Antonio L. Bartorelli, Alexandre Abizaid, Patrick W. Serruys

Journal of the American College of Cardiology

Article2014

TCT-619 ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold

Bernard De Bruyne, Gábor G. Tóth, Yoshinobu Onuma, Patrick W. Serruys

Journal of the American College of Cardiology

TCT-415 Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?

Abstract

Discussion(0)

Related publications

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

ACUTE RECOIL FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: THE ABSORB II TRIAL

TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

TCT-36 One-year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis From the ABSORB Cohort B and the ABSORB EXTEND Trials.

TCT-619 ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold